EN DE
STOCK COMPARISON

PolyPeptide Group vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how PolyPeptide Group (PLYGF) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: PolyPeptide Group trades at $54.42 versus a fair value of $4.36 (-92%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).
PolyPeptide Group
PLYGF · USD · Healthcare
-92%
upside to fair value
overvalued
Price$54.42
Fair Value$4.36
Quality44/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-53%
upside to fair value
overvalued
Price¥54.62
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

PolyPeptide GroupJiangsu Hengrui Medicine Co
Valuation
—P/E (TTM)43.6×
3.65×P/S (TTM)10.84×
4.17×P/B5.76×
38.2×EV/EBITDA33.0×
—PEG0.93×
—Dividend yield0.4%
—Dividend per share¥0.20
Profitability
-5%Net margin25%
10%Operating margin32%
-6%Return on equity15%
1%Return on assets9%
Growth
10%Revenue growth (YoY)13%
11.4%Avg. growth/yr (3Y)13.9%
—Avg. growth/yr (5Y)2.5%
Balance & size
0.32×Debt / equity—
$1BMarket cap$52B
expensiveGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 2 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

PolyPeptide Groupof which business quality 44 · market factors 64 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 46
ProfitabilityMargins and returns on capital today
11
63
Quality GrowthAre margins and returns improving?
71
41
CashflowEarnings quality: real cash, not paper profit
24
82
Fin. StrengthBalance sheet, leverage, solvency risk
52
100
InvestmentDisciplined investing over empire-building
45
27
Low VolatilityCalm price path (market factor)
36
78
MomentumPrice trend over the last 3–12 months (market factor)
75
35
52W MomentumDistance to the 52-week high (market factor)
78
29
Net IssuanceBuybacks instead of dilution
81
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

PolyPeptide Group

Earnings-Based$0.85
Dividend Discount$3.93
Multiples$3.70
Asset-Based$6.91
Economic Profit$0.85

8 of 8 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

PolyPeptide Group
Bear $3.01Fair Value $4.36Bull $5.72
$54.42 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.62 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

PolyPeptide Group · Healthcare

Quality score44 · below median
Fair value upside-92% · bottom 25%

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-53% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: PolyPeptide Group trades at $54.42 versus a fair value of $4.36 (-92%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →
PolyPeptide Group · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to PolyPeptide Group

Alphabet Inc Class C vs Verizon CommunicationsAlphabet Inc Class C vs At&tAlphabet Inc Class C vs NetEaseAmazon.com vs Toyota Motor Corporation

Related to Jiangsu Hengrui Medicine Co

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.